Latest News & Updates
Governor Signs Legislation Taking First Step to Improving Access to Biomarker Testing for Floridians
June 27, 2024
Gov. Ron DeSantis signed HB885 into law on June 18th, which expands patient access to biomarker testing, a key tool used by physicians to identify the most effective treatment of cancer and other diseases. In the case of a cancer diagnosis, biomarker testing allows doctors to develop a personalized treatment plan. It opens the door…
CMS Opens Registration for Second Oncology Payment Model Cohort on July 1
June 24, 2024
The Centers for Medicare & Medicaid Services Innovation Center (CMMI) announced it is reopening the Enhancing Oncology Model for a second cohort of participants and payers. The second cohort will begin on July 1, 2025, and end on June 30, 2030, for a 5-year model performance period. For more details and eligibility criteria, please read…
Bipartisan, ASCO-Endorsed Prior Authorization Bill Reintroduced in Congress
June 24, 2024
Bipartisan members of the Unites States House of Representatives and Senate have reintroduced the Association for Clinical Oncology (ASCO)-endorsed Improving Seniors’ Timely Access to Care Act (H.R.8702/S.4532) to streamline prior authorization within Medicare Advantage (MA) plans. The bill currently has 175 combined cosponsors (45 senators and 130 representatives). Last Congress, this legislation unanimously passed in…
Nationwide Recall of Docetaxel Issued Over Particulate Concerns
June 7, 2024
On May 28, Sagent Pharmaceuticals announced a voluntary nationwide recall of two lots of docetaxel injection (80 mg per 8 mL multidose vials and 160 mg per 16 mL multidose vials). The move was prompted by a customer complaint regarding possible particulate matter. Although no adverse events have been reported thus far, injection of particulate…
FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory follicular lymphoma
June 26, 2024
On June 26, 2024, the Food and Drug Administration granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.), a bispecific CD20-directed CD3 T-cell engager, for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
FDA approves blinatumomab as consolidation for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia
June 24, 2024
On June 14, 2024, the Food and Drug Administration approved blinatumomab (Blincyto, Amgen Inc.) for adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (Ph-negative BCP ALL) in the consolidation phase of multiphase chemotherapy.
FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer
June 24, 2024
On June 21, 2024, the Food and Drug Administration granted accelerated approval to adagrasib (Krazati; Mirati Therapeutics, Inc., a Bristol Myers Squibb company) plus cetuximab for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC), as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
FDA approves pembrolizumab with chemotherapy for primary advanced or recurrent endometrial carcinoma
June 17, 2024
On June 17, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma.
Get More from FLASCO With Your Partnership
The Corporate Partnership Program allows FLASCO to expand our offerings to our partneres. Every FLASCO meeting also provides the industry representative with opportunities to educate our partners. When you send representatives to a FLASCO meeting, you are allowing them to share their knowledge, as well as receive the same knowledge as our members by participating within the educational sessions. This helps ensure that the hematology and oncology community at large are learning, sharing best practices, and finding solutions to problems together.
Corporate Partners
Upcoming Events
Click to view full events calendar.
August 8, 2024 5:00 pm
Living With Breast Cancer
September 5, 2024
Living With Blood Cancer
September 7, 2024 8:00 am
FLASCO Clinical Oncology Series: Multiple Myeloma
We're Here to Help Contact Us
Add your name, email & message below:
